# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roth MKM analyst Jonathan Aschoff maintains BioRestorative Therapies (NASDAQ:BRTX) with a Buy and raises the price target fr...
BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate...
BioRestorative Therapies shares are trading higher Monday after the company announced it has received notice from the Nasdaq St...